Our findings suggest that the effect of hospital volume and surgical treatment delay on overall survival of cancer patients should be considered in formulating or revising national health policy.

No abstract

Little was known about work situation and work-related difficulties, including housework after stomach cancer diagnosis. We aimed to compare employment status and work-related difficulties between stomach cancer survivors and the general population. We enrolled 408 stomach cancer survivors from two hospitals 28 months after diagnosis and 994 representative volunteers from the general population from 15 geographic districts. Working was defined as being employed (including self-employed) and nonworking as being retired or a homemaker. Nonworking was significantly higher among stomach cancer survivors (46.6%) than in the general population (36.5%). Compared with the general population, the survivors had more fatigue in performing both housework (adjusted odds ratio (aOR) ¼ 2.08; 95% confidence interval (95% CI) ¼ 1.01 -4.29) and gainful work (aOR ¼ 4.02; 2.55 -6.33). More cancer survivors had reduced working hours (aOR ¼ 1.42; 95% CI ¼ 4.60 -28.35) and reduced work-related ability (aOR ¼ 6.11; 95% CI ¼ 3.64 -10.27) than did the general population. The association of nonworking with older age and being female was significantly more positive for survivors than for the general population. Among survivors, poorer Eastern Cooperation Oncology Group Performance Status and receiving total gastrectomy were positively associated with nonworking. Stomach cancer survivors experienced more difficulties in both housework and gainful employment than did the general population. Our findings on stomach cancer survivors' work-related difficulties and the predictors of nonworking will help physicians guide patients towards more realistic postsurgical employment plans.

Background:We evaluated the association between polymorphisms of cytochrome P450 2A6 (CYP2A6)/excision repair cross-complementation group 1 (ERCC1)/X-ray repair cross-complementing group 1(XRCC1) and treatment outcomes of metastatic gastric cancer (MGC) patients treated with S-1/cisplatin.Methods:Among MGC patients (n=108), who received S-1 (40 mg m−2 b.i.d., days 1–14) and cisplatin (60 mg m−2, day 1) every 3 weeks, we analysed the wild-type allele (W) and variants (V) of CYP2A6 (*4, *7, *9, *10), and the polymorphisms of ERCC1 (rs11615, rs3212986) and XRCC1 (rs25487).Results:Patients having fewer CYP2A6 variants had better response rates (W/W vs W/V other than *1/*4 vs V/V or *1/*4=66.7 vs 58.3 vs 32.3% P=0.008), time to progression (TTP) (7.2 vs 6.1 vs 3.5 months, P=0.021), and overall survival (23.2 vs 15.4 vs 12.0 months, P=0.004). ERCC1 19442C>A (rs3212986) was also associated with response rate (C/C, 46.7% vs C/A, 55.3% vs A/A, 87.5%) (P=0.048) and TTP (4.4 vs 7.6 vs 7.9 months) (P=0.012). Patients carrying both risk genotypes of CYP2A6 (V/V or 1/*4) and ERCC1 19442C>A (C/C) vs those carrying none showed an adjusted odds ratio of 0.113 (P=0.004) for response, and adjusted hazard ratios of 3.748 (P=0.0001) for TTP and 2.961 (P=0.006) for death.Conclusion:Polymorphisms of CYP2A6 and ERCC1 19442C>A correlated with the efficacy of S-1/cisplatin.

In the present study, a novel droplet-merging technique is proposed, which enables two nanoliter or picoliter droplets to merge in a straight microchannel with high precision. Two dispersed phase fluids are supplied respectively from two side channels in a certain range of flow rates to generate droplets of different sizes or different viscosities in a regularly alternating mode at a cross-channel intersection prior to the straight microchannel, in such a manner that the droplets are spontaneously synchronized by themselves due to the competition of the two interfaces formed at the cross-channel intersection. Then they are autogeneously merged in the downstream straight microchannel with or without a sudden expansion of the cross section, due to their velocity difference which is induced as they are transported aboard the continuous phase fluid. This droplet-merging method has no desynchronization or secondary-merging problems. Thus, it can be applied efficiently to mixing or encapsulating one target sample with another material for the purposes of nanoparticle synthesis, hydrogel-bead production, cell transplantation and so forth.